Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus Target Price from Analysts
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...
Immunic (IMUX) Has a New Rating from William Blair
Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Yahoo Finance2d
Immunic, Inc. (IMUX)
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Yahoo Finance6d
Immunic, Inc. (IMUX)
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...
Yahoo Finance6d
Immunic, Inc. (IMUX)
At close: 28 March at 4:00:00 pm GMT-4 ...